StocksFundsScreenerSectorsWatchlists
HROW

HROW - Harrow Health Inc Stock Price, Fair Value and News

12.79USD+0.06 (+0.47%)Delayed as of 28 Mar 2024, 12:00 pm ET

Market Summary

HROW
USD12.79+0.06
Delayedas of 28 Mar 2024, 12:00 pm
0.47%

HROW Alerts

  • 2 major insider buys and 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

HROW Stock Price

View Fullscreen

HROW RSI Chart

HROW Valuation

Market Cap

404.4M

Price/Earnings (Trailing)

-16.57

Price/Sales (Trailing)

3.11

EV/EBITDA

-385.92

Price/Free Cashflow

169.93

HROW Price/Sales (Trailing)

HROW Profitability

EBT Margin

-18.21%

Return on Equity

-34.67%

Return on Assets

-7.82%

Free Cashflow Yield

0.59%

HROW Fundamentals

HROW Revenue

Revenue (TTM)

130.2M

Rev. Growth (Yr)

78.83%

Rev. Growth (Qtr)

6.1%

HROW Earnings

Earnings (TTM)

-24.4M

Earnings Growth (Yr)

-967.11%

Earnings Growth (Qtr)

-108.34%

Breaking Down HROW Revenue

52 Week Range

12.7028.25
(Low)(High)

Last 7 days

9.6%

Last 30 days

7.8%

Last 90 days

8.8%

Trailing 12 Months

-40.5%

How does HROW drawdown profile look like?

HROW Financial Health

Current Ratio

2.83

HROW Investor Care

Shares Dilution (1Y)

17.61%

Diluted EPS (TTM)

-0.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202392.6M102.7M114.2M130.2M
202279.2M84.3M88.5M88.6M
202152.5M62.6M66.9M72.5M
202050.7M45.2M46.9M48.9M
201944.8M47.9M49.9M51.2M
201830.4M34.1M37.7M41.4M
2017022.4M24.6M26.8M
2016013.1M16.0M19.1M
20153.2M4.5M6.8M9.7M
20142.7M2.3M2.0M1.7M
20133.7M3.3M3.0M0
20120004.0M

Tracking the Latest Insider Buys and Sells of Harrow Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 22, 2024
baum mark l
bought
104,310
11.59
9,000
chief executive officer
Mar 20, 2024
opaleye management inc.
bought
488,290
9.65
50,600
-
Mar 01, 2024
saharek john p.
acquired
43,750
8.75
5,000
ceo of imprimisrx
Feb 20, 2024
saharek john p.
sold
-134,613
10.67
-12,616
ceo of imprimisrx
Feb 20, 2024
baum mark l
sold
-638,450
10.67
-59,836
chief executive officer
Feb 20, 2024
boll andrew r.
acquired
480,150
10.67
45,000
chief financial officer
Feb 20, 2024
boll andrew r.
sold
-197,182
10.67
-18,480
chief financial officer
Feb 20, 2024
baum mark l
acquired
1,600,500
10.67
150,000
chief executive officer
Feb 20, 2024
saharek john p.
acquired
320,100
10.67
30,000
ceo of imprimisrx
Feb 07, 2024
baum mark l
acquired
118,734
7.71
15,400
chief executive officer

1–10 of 50

Which funds bought or sold HROW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
56.00
56.00
-%
Mar 11, 2024
VANGUARD GROUP INC
added
2.77
-5,033,680
20,255,800
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
169
635,511
1,214,550
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
3.03
-41,397
168,750
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
10.79
-27,000
176,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-24,235
85,624
-%
Feb 15, 2024
BARCLAYS PLC
added
55.63
109,000
624,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
807,318
807,318
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-75,618
267,165
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
11.00
11.00
-%

1–10 of 44

Are Funds Buying or Selling HROW?

Are funds buying HROW calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HROW
No. of Funds

Unveiling Harrow Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
kaufman daniel louis
5.43%
1,907,332
SC 13G/A
Feb 13, 2024
vanguard group inc
5.15%
1,808,552
SC 13G
Feb 09, 2024
opaleye management inc.
10.88%
3,820,000
SC 13G/A
Jan 29, 2024
blackrock inc.
6.3%
2,220,538
SC 13G
Jan 09, 2024
private capital management, llc
10.34%
3,630,496
SC 13G
Nov 24, 2023
kaufman daniel louis
5.37%
1,885,032
SC 13G
Aug 18, 2023
baum mark l
9.5%
3,488,361
SC 13D/A
Jan 20, 2023
opaleye management inc.
12.82%
3,775,000
SC 13G/A
Feb 14, 2022
ophir asset management pty ltd
7.08%
1,905,354
SC 13G
Jan 26, 2022
opaleye management inc.
12.2%
3,285
SC 13G/A

Recent SEC filings of Harrow Health Inc

View All Filings
Date Filed Form Type Document
Mar 25, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 21, 2024
8-K
Current Report
Mar 20, 2024
8-K
Current Report
Mar 19, 2024
10-K
Annual Report
Mar 19, 2024
8-K
Current Report
Mar 06, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading

What is the Fair Value of HROW?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Harrow Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.6B
85.2B
-0.84% 1.87%
10.83
4.47
6.46% 95.94%
333.8B
60.1B
-3.08% 18.97%
914.53
5.55
1.40% -97.49%
156.9B
46.5B
-0.94% -29.07%
-113.02
3.37
42.59% -114.62%
153.4B
28.2B
-2.65% 20.18%
22.84
5.44
7.09% 2.52%
91.0B
27.1B
1.44% -6.08%
16.06
3.35
-0.60% 23.36%
16.2B
15.8B
6.68% 47.26%
-28.08
1.02
6.17% 76.47%
MID-CAP
4.6B
1.7B
-15.20% 8.04%
12.8
2.74
49.61% 324.78%
4.3B
4.7B
-2.22% -15.29%
-335.7
0.92
4.58% 90.97%
3.8B
8.8B
12.34% 25.79%
-6.47
0.44
7.79% -163.11%
2.1B
644.4M
-19.16% 20.49%
15.22
3.25
29.14% 50.51%
SMALL-CAP
1.8B
700.5M
20.31% -
-1.29
2.63
16.26% -147.49%
24.2M
70.0M
1.33% -38.14%
0.35
0.34
-19.54% 888.31%
18.7M
-
-10.40% 69.70%
-1.01
0.22
2882.68% -138.52%
14.8M
111.1M
-18.24% -6.20%
-0.93
0.13
-10.43% 84.90%
929.3K
20.0M
-54.17% -94.76%
-0.07
0.05
137.71% 66.04%

Harrow Health Inc News

Latest updates
Defense World • 26 Mar 2024 • 08:47 am
Defense World • 26 Mar 2024 • 06:21 am
InvestorsObserver • 25 Mar 2024 • 05:58 pm
Yahoo Finance • 21 Mar 2024 • 01:55 pm
CNN • 4 months ago

Harrow Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue6.1%36,355,00034,265,00033,470,00026,103,00020,329,00022,823,00023,323,00022,120,00020,188,00018,711,00018,134,00015,443,00014,595,00014,399,0008,060,00011,817,00012,604,00012,755,00013,516,00012,290,00011,384,000
Gross Profit3.5%25,053,00024,198,00023,470,00017,832,00014,164,00016,102,00016,789,00016,157,00015,108,00013,764,00013,717,00011,673,00010,658,00010,703,0004,856,0008,191,0009,039,0008,694,0008,291,0008,392,0007,282,000
Operating Expenses33.3%29,928,00022,454,00021,118,00016,622,00015,942,00016,196,00015,099,00014,056,00016,863,00017,481,0009,548,0008,756,0008,032,0009,106,0008,066,0008,819,0008,113,00013,092,0009,058,0008,948,0009,445,000
  S&GA Expenses24.6%26,212,00021,033,00019,957,00015,888,00015,239,00015,421,00014,185,00013,398,00012,672,00011,356,0009,123,0008,164,0007,441,0008,436,0006,954,0008,416,0007,689,0008,608,0008,248,0008,543,0009,012,000
  R&D Expenses134.8%3,336,0001,421,0001,161,000734,000703,000775,000914,000658,0003,942,0006,125,000425,000592,000591,000670,000749,000403,000424,000444,000810,000405,000433,000
EBITDA Margin-111.4%-0.010.06-0.01-0.08-0.06-0.15-0.18-0.15-0.15-0.100.140.18-0.10--------
Interest Expenses-10.9%5,124,0005,749,0005,704,0004,747,0001,858,0001,800,0001,794,0001,792,0001,924,0001,685,0001,314,000513,000-2,734,000498,000-505,000-560,000-561,000-620,000-716,000-603,000-689,000
Income Taxes-134.8%-535,0001,539,000-15,000-288,000-35,00040,000--------------
Earnings Before Taxes-239.5%-9,683,000-2,852,000-4,244,000-6,931,0001,055,000-6,429,000-6,199,000-2,438,000-7,285,000-8,328,000-2,478,000217,0001,145,0008,623,000-260,000-12,923,0002,600,000-11,630,000-2,420,00011,333,00018,130,000
EBT Margin-60.3%-0.18-0.11-0.16-0.20-0.16-0.25-0.29-0.26-0.25-0.140.120.19-0.07--------
Net Income-108.3%-9,148,000-4,391,000-4,229,000-6,643,0001,055,000-6,464,000-6,239,000-2,438,000-7,418,000-8,328,000-2,478,000217,0001,149,0008,638,000-237,000-12,907,0002,657,000-11,469,000-2,378,00011,358,00018,130,000
Net Income Margin-50.7%-0.19-0.12-0.16-0.20-0.16-0.26-0.29-0.26-0.25-0.140.120.19-0.07--------
Free Cashflow592.0%8,502,000-1,728,0004,316,000-8,710,000-4,590,000-1,465,0004,600,000563,000-1,627,000-2,365,0004,291,0002,997,000-648,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets9.1%31228622421715799.0098.0098.0098.0010310756.0057.0059.0049.0047.0059.0055.0065.0067.0049.00
  Current Assets26.5%13911060.0052.0011864.0065.0062.0061.0091.0093.0041.0041.0041.0030.0026.0036.0032.0038.0039.0033.00
    Cash Equivalents12.9%74.0066.0023.0019.0096.0045.0046.0042.0042.0058.0073.006.004.006.004.004.005.004.004.004.007.00
  Inventory21.8%11.009.009.009.007.005.005.004.004.004.004.004.004.004.004.004.003.002.003.002.002.00
  Net PPE-3.0%4.004.004.004.003.003.003.003.003.005.005.004.004.005.005.005.005.005.006.006.006.00
  Goodwill0%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.002.002.002.00
Liabilities14.8%24221120219613098.0093.0088.0087.0087.0084.0028.0031.0035.0034.0032.0032.0031.0030.0029.0025.00
  Current Liabilities159.3%49.0019.0023.0018.0019.0018.0013.009.0010.0010.008.0010.0011.0014.0013.0013.0012.0011.0010.0011.0012.00
Shareholder's Equity-7.1%70.0076.0022.0022.0028.001.005.0010.0011.0016.0023.0028.0027.0025.0015.0015.0027.0024.0035.0037.0025.00
  Retained Earnings-7.3%-133-124-120-116-109-110-104-97.84-95.41-87.99-79.66-77.18-77.40-78.55-87.19-86.95-74.04-76.70-65.23-62.85-74.21
  Additional Paid-In Capital2.1%20520014313813711211010810710510310510510410310210210110010099.00
Shares Outstanding0.1%35.0035.0030.0030.0030.0027.0027.0027.0027.0027.0026.0026.00---------
Minority Interest0%-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.33-0.31-0.29-0.23-0.07-0.02-
Float-------159---196---125---205--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations819.9%8,696-1,2084,566-8,214-3,712-4104,860967-1,490-2,0765,4403,208-5662,667-2,651-5501,652-70.00844-1,476-36.00
  Share Based Compensation14.0%4,5003,9485,2901,6333,0082411,7352,0163,2612.004818551,096559271533594159110713813
Cashflow From Investing99.0%-203-20,131-1,249-130,970-5.00-1,069-259-410-14,197-12,9348,669-224-90.00-281-337-273-969-79.00-461-324-852
Cashflow From Financing-100.0%-18.0064,19518962,16255,028--111-776-2.0015.0052,238-781-770-7612,966-2.00635-413-455-7731,411

HROW Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues:  
Total revenues$ 130,193,000$ 88,595,000
Cost of sales(39,640,000)(25,383,000)
Gross profit90,553,00063,212,000
Operating expenses:  
Selling, general and administrative83,090,00058,243,000
Research and development6,652,0003,050,000
Impairment of intangible assets380,000
Total operating expenses90,122,00061,293,000
Income from operations431,0001,919,000
Other (expense) income:  
Interest expense, net(21,324,000)(7,244,000)
Equity in losses of unconsolidated entities(11,133,000)
Investment gain (loss) from Eton Pharmaceuticals3,092,000(2,914,000)
Loss on extinguishment of debt(5,465,000)
Gain on sale of non-ophthalmology assets5,259,000
Other (expense) income, net(444,000)102,000
Total other expense, net(24,141,000)(15,930,000)
Loss before income tax provision(23,710,000)(14,011,000)
Income tax provision(701,000)(75,000)
Net loss attributable to Harrow, Inc.$ (24,411,000)$ (14,086,000)
Basic net loss per share of common stock$ (0.75)$ (0.51)
Diluted net loss per share of common stock$ (0.75)$ (0.51)
Weighted average number of shares of common stock outstanding, basic32,616,77727,460,968
Weighted average number of shares of common stock outstanding, diluted32,616,77727,460,968
Product Sales Net [Member]  
Revenues:  
Total revenues$ 117,447,000$ 83,524,000
Other Revenues [Member]  
Revenues:  
Total revenues$ 12,746,000$ 5,071,000

HROW Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 74,085,000$ 96,270,000
Investment in Eton Pharmaceuticals8,681,0005,589,000
Accounts receivable, net36,261,0006,249,000
Inventories10,867,0006,541,000
Prepaid expenses and other current assets9,588,0003,611,000
Total current assets139,482,000118,260,000
Property, plant and equipment, net3,521,0003,486,000
Capitalized software costs, net2,138,0002,112,000
Deferred financing costs1,950,000
Operating lease right-of-use assets, net6,785,0007,513,000
Intangible assets, net159,906,00023,725,000
Goodwill332,000332,000
TOTAL ASSETS312,164,000157,378,000
Current liabilities  
Accounts payable and accrued expenses24,581,00013,771,000
Accrued rebates and copay assistance18,432,000
Accrued payroll and related liabilities5,450,0004,025,000
Deferred revenue and customer deposits75,000113,000
Current portion of operating lease obligations806,000723,000
Total current liabilities49,344,00018,632,000
Operating lease obligations, net of current portion6,524,0007,332,000
Accrued expenses, net of current portion2,713,000
Notes payable, net of unamortized debt discount and issuance costs183,172,000104,174,000
TOTAL LIABILITIES241,753,000130,138,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY  
Common stock, $0.001 par value, 50,000,000 shares authorized, 35,168,260 and 29,901,530 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively35,00030,000
Additional paid-in capital204,635,000137,058,000
Accumulated deficit(133,904,000)(109,493,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY70,766,00027,595,000
Noncontrolling interests(355,000)(355,000)
TOTAL STOCKHOLDERS’ EQUITY70,411,00027,240,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 312,164,000$ 157,378,000
HROW
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEwww.harrowinc.com
 EMPLOYEES217

Harrow Health Inc Frequently Asked Questions


What is the ticker symbol for Harrow Health Inc? What does HROW stand for in stocks?

HROW is the stock ticker symbol of Harrow Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harrow Health Inc (HROW)?

As of Wed Mar 27 2024, market cap of Harrow Health Inc is 404.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HROW stock?

You can check HROW's fair value in chart for subscribers.

What is the fair value of HROW stock?

You can check HROW's fair value in chart for subscribers. The fair value of Harrow Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harrow Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HROW so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harrow Health Inc a good stock to buy?

The fair value guage provides a quick view whether HROW is over valued or under valued. Whether Harrow Health Inc is cheap or expensive depends on the assumptions which impact Harrow Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HROW.

What is Harrow Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, HROW's PE ratio (Price to Earnings) is -16.57 and Price to Sales (PS) ratio is 3.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HROW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Harrow Health Inc's stock?

In the past 10 years, Harrow Health Inc has provided 0.052 (multiply by 100 for percentage) rate of return.